Phase 2 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form before taking part in the research
• Men or women aged 50 or older at the time of signing the consent form
• People who have abnormal blood vessel growth (called CNV) under or involving the central area of the retina (the macula), caused by a condition known as wet age-related macular degeneration (wet AMD)
• People whose vision in the study eye falls within a specific range on a standardised eye chart test (between 19 and 78 ETDRS letters, inclusive) at the start of the trial

Who may not be able to join:

• People whose study eye has other eye conditions or health conditions that, in the investigator's judgement, could interfere with treatment results or make the results difficult to interpret
• People whose study eye has glaucoma that cannot be controlled
• People who have an active infection or inflammation in or around either eye
• People whose non-study eye has severe vision loss
• People whose study eye received an anti-VEGF injection (a type of eye treatment) within 90 days before the start of the trial
• People whose study eye received an anti-complement treatment within 90 days before the start of the trial
• People whose study eye has ever received the specific study drug (IBI302) at any point before the trial
• People with high blood pressure that cannot be controlled
• People whose blood sugar control measure (HbA1c) was above 10.0% within 28 days before the screening visit
• People who meet any other exclusion criteria set out in the trial protocol (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.